Cargando…
Results of a worldwide external quality assessment of cfDNA testing in lung Cancer
BACKGROUND: Circulating cell free DNA (cfDNA) testing of plasma for EGFR somatic variants in lung cancer patients is being widely implemented and with any new service, external quality assessment (EQA) is required to ensure patient safety. An international consortium, International Quality Network f...
Autores principales: | Fairley, Jennifer A., Cheetham, Melanie H., Patton, Simon J., Rouleau, Etienne, Denis, Marc, Dequeker, Elisabeth M. C., Schuuring, Ed, van Casteren, Kaat, Fenizia, Francesca, Normanno, Nicola, Deans, Zandra C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275131/ https://www.ncbi.nlm.nih.gov/pubmed/35820813 http://dx.doi.org/10.1186/s12885-022-09849-x |
Ejemplares similares
-
IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing
por: Deans, Zandra C., et al.
Publicado: (2019) -
International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA
por: Keppens, Cleo, et al.
Publicado: (2018) -
Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
por: Deans, Zandra C., et al.
Publicado: (2017) -
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)
por: Fenizia, Francesca, et al.
Publicado: (2021) -
External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme
por: Esposito Abate, Riziero, et al.
Publicado: (2022)